Research indicates patients who undergo a single 28-Gy session experience similar outcomes to those who have four 12-Gy sessions, pointing to safer, faster treatment.
Safe treatment for lung metastases can be effectively achieved faster than believed by using an ultrasound stereotactic body radiation therapy (SBRT) method, according to newly presented research.
In a presentation during the American Society of Radiation Oncology (ASTRO) annual meeting, investigators from the University of California at San Francisco (UCSF) revealed the results of their randomized Phase 2 trial. The study was conducted across 13 medical centers throughout New Zealand and Australia.
The study included 90 patients who had limited disease spread from one-to-three lung metastases. According to their results, patient who received on 28-Gy session with SBRT experienced the same results as patients who had four 12-Gy sessions each.
Ultimately, the research team, led by Sue Yom, Ph.D., professor of radiation oncology and otolaryngology-head and neck surgery at UCSF, focused on safety, and they assessed it by looking at the number of patient severe adverse rates.
They found both regimens were equally tolerable. For patients in the one-treatment group, the rate of grade 3+ events within a year post-treatment was 5 percent. It was 3 percent for patients in the four-treatment group. In addition, at a year post-treatment, disease-free survival rates were similar – 59 percent for one-treatment participants, and 60 percent for those receiving four treatments. Both groups also had similar local control rates – 93 percent and 95 percent, respectively.
For more coverage based on industry expert insights and research, subscribe to the Diagnostic Imaging e-Newsletter here.
Ultimately, the researchers said, these types of shortened treatments bode well for radiation oncology, particularly during the COVID-19 pandemic. If further research produces similar findings, Yom said, it is possible that patients who have few lung metastases could be treated expeditiously and safely with only one treatment, potentially reducing hospital time and improving quality of life.
Support for this study came from the Trans-Taman Radiation Oncology Group.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.